A new study has found for the first time that magnetoelectric nanoparticles—tiny, wirelessly controlled particles activated ...

Vancouver, Canada, November 4th, 2025, FinanceWire Equity Insider News Commentary – The precision medicine sector reached ...

Braveheart Bio, a late clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy (HCM) and related conditions, today announced its launch with $185 million in ...

"It offers huge potential to boost food security, cut pesticide use, increase crop yields and enhance disease resistance and we are backing it with a multimillion-pound investment," the Department for ...

Rigel Pharmaceuticals, Inc. , a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the third quarter ended September 30, 2025, ...

South Rampart Pharma is working to develop an oral small molecule non-opioid pain treatment which has generated early positive clinical data as a therapy for acute and chronic pain, as well as ...